业绩稳健增长，盈利能力显著提升。2025 年上半年，公司在收入端保持稳健增长的同时，盈利能力实 现大幅提升，归母净利润增速（25.51%）超过营收增速（3.70%）。利润增长主要得益于公司经营质量 的持续优化：一是成本费用管控成效显著，报告期内销售费用和管理费用同比分别下降2.27%和 8.22%；二是产品结构优化带动毛利率提升，核心的仪器仪表业务毛利率同比提升1.18 个百分点，其中 工业过程分析系统业务收入同比增长19.17%，成为重要增长引擎；三是资产质量改善，信用减值损失 由去年同期的-737.95 万元转为本期的290.70 万元，对利润形成正向贡献，反映出公司回款管理加强、 客户结构优化的积极成果。 事件：公司发布2025 年半年度报告，2025 年上半年，公司实现营业收入5.96 亿元，同比增长4%；实现 归母净利润6197.41 万元，同比增长26%；扣非后归母净利润5073.08 万元，同比增长37%。 碳监测与高端制造双轮驱动，国产替代打开新空间。公司前瞻布局，将碳监测业务作为未来发展的"第 二增长极"。公司已构建起从碳排放在线监测系统、碳计量数据管理终端到碳账户管理平台的"智能装备 +智 ...

Core Viewpoint - The customs system has announced procurement intentions for laboratory instruments and reagents, totaling a budget of 118 million yuan, with 33 items identified for procurement scheduled between July and October 2025 [1][2]. Procurement Summary - The procurement includes various laboratory instruments such as gas chromatographs, liquid chromatographs, mass spectrometers, and other analytical equipment, aimed at enhancing detection capabilities and efficiency in customs operations [2][4]. - Specific items listed for procurement include: - Pathogen nucleic acid detection reagents and consumables with a budget of 1.34 million yuan [3]. - Various laboratory instruments for different customs centers, including: - Color Doppler ultrasound diagnostic machines, automatic biochemical analyzers, and high-pressure sterilizers [5][6]. - A total of 42 instruments planned for procurement by the Nanning Customs Technical Center, including nitrogen generators and automatic mercury analyzers [6]. - The Guizhou International Travel Health Care Center plans to procure 18 devices with a budget of 5.27 million yuan [5]. - The procurement aims to meet the increasing demands for testing and analysis in customs, ensuring compliance with national standards and improving operational efficiency [5][6][7].

Core Viewpoint - The article highlights various high-paying job opportunities in the analytical instrument sector, emphasizing the demand for skilled professionals in sales and technical roles across different companies [2][3][4][5][7][9][10][12][16][18]. Group 1: Job Opportunities - Shimadzu is hiring for a Sales Representative position in Chengdu with a salary range of 8k-13k per month [2]. - Agilent is looking for an Application Engineer specializing in Gas Chromatography in Shanghai, offering a salary between 25k-35k per month [4]. - Pannuo is seeking a Mass Spectrometry Technical Leader in Shanghai, with a salary range of 50k-90k per month [5]. - Zhonghang Shijinshi is recruiting a Nuclear Power Materials Sales Representative in Langfang, with a salary of 15k-20k per month [7]. - Meipuda is hiring a Client Manager in Shanghai, offering a salary range of 10k-15k per month [9]. Group 2: Job Requirements - For the Sales Representative position at Shimadzu, candidates should have a bachelor's degree in relevant fields and at least 2 years of sales experience, with a strong emphasis on communication skills and customer satisfaction [3]. - The Application Engineer role at Agilent requires a bachelor's or master's degree in analytical chemistry or related fields, along with over 7 years of relevant work experience [4]. - The Mass Spectrometry Technical Leader position at Pannuo demands a master's or doctoral degree with over 5 years of R&D experience in mass spectrometry [6]. - The Nuclear Power Materials Sales Representative role requires a bachelor's degree and at least 3 years of sales experience in the nuclear power or electricity industry [8]. - The Client Manager position at Meipuda requires a bachelor's degree and at least 2 years of relevant work experience, with strong communication skills [10].

Core Insights - The article highlights a 10.1% quarter-on-quarter increase in inquiry volume for scientific instruments in Q2 2025, with gas chromatography, infrared spectroscopy, and ultraviolet spectrophotometry being the top three categories [1][4][6]. Inquiry Volume Analysis - In Q2 2025, the majority of inquiries came from industrial enterprises, followed by universities, with industrial inquiries being more numerous but university inquiries having higher individual values [4]. - Among the top 10 inquiry categories, six remained consistent from Q1 to Q2, including gas chromatography, infrared spectroscopy, and ultraviolet spectrophotometry [6]. Domestic vs. Imported Instruments - The inquiry statistics indicate a rising demand for domestic instruments, with a 19% requirement for domestic products and 3% for imports, reflecting a 1.7 percentage point increase for domestic and a 0.2 percentage point increase for imports [8]. Service Activities and AI Integration - Q2 2025 saw a variety of service activities, including offline resource matching and visits to major buyers, enhancing communication between suppliers and buyers [10][13]. - The launch of the AI assistant "Yizhi Xing" during the ACCSI2025 CMO Summit aims to improve instrument selection accuracy, leveraging 26 years of industry data and over 500 daily updates [17][19]. Membership and Platform Benefits - The "Yixin Tong" membership program offers manufacturers a dedicated website and access to over 25 million professional users, enhancing product exposure and brand empowerment [20]. - The "Instrument Selection" service platform has partnered with over 2,000 domestic and international manufacturers, facilitating efficient access to instrument buyers with an annual procurement amount exceeding 65 billion [22].

Core Viewpoint - Nanwei Technology (688690) is experiencing growth driven by the booming GLP-1 peptide drug market, leading to increased investment in new drug research and production capacity by domestic and international pharmaceutical companies [2][3]. Group 1: Business Performance - The company's main revenue for Q1 2025 was 189 million yuan, a year-on-year increase of 22.39%, with a net profit attributable to shareholders of 29.22 million yuan, up 72.98% year-on-year [7]. - The gross profit margin for the chromatography filler business is high, accounting for approximately 60% of the company's revenue, which has improved overall profitability [4]. Group 2: Market Strategy - The company is focusing on the antibody new drug projects as a key area for replacing imported products, enhancing competitiveness through continuous R&D investment and product innovation [3]. - To address domestic competition, the company is building a comprehensive chromatography technology platform, providing integrated solutions to avoid price wars in single product categories [6]. Group 3: Mergers and Acquisitions - The acquisition of two instrument companies enhances the company's product line from chromatography fillers to protein purification equipment, improving business and product layout and achieving synergy in customer expansion and market sales [5]. Group 4: Future Outlook - The company is accelerating its overseas market layout and enhancing its overseas sales capabilities to increase application opportunities for its filler products among international clients [3][6].

Core Viewpoint - The customs system has announced procurement intentions for laboratory reagents and consumables, totaling a budget of 143 million yuan, with 18 items planned for procurement between June and October 2025 [1][2]. Procurement Overview - The procurement includes various laboratory instruments such as gas chromatography-triple quadrupole mass spectrometers, gas chromatography-mass spectrometers, inductively coupled plasma mass spectrometers, gas chromatographs, and high-performance liquid chromatographs [2][4]. - The total budget for the procurement is 143 million yuan, with specific projects outlined for different customs technical centers [2][4]. Specific Projects - Jiangxi International Travel Health Care Center plans to procure laboratory instruments including high-pressure sterilizers and digital multifunctional X-ray machines, with a budget of 1.28 million yuan [4]. - Urumqi Customs Technical Center aims to procure reagents and consumables worth 4.1 million yuan, including microbiological and molecular biology reagents [4][6]. - The procurement plan for the Nanning Customs Technical Center includes a budget of 8 million yuan per year for reagent consumables from 2025 to 2026 [6][7]. Equipment and Technology Upgrades - The procurement will enhance laboratory detection capabilities, with a focus on modernizing and standardizing laboratory equipment [7][9]. - Specific equipment includes portable chemical hazard detection instruments, A and B level protective clothing, and various monitoring devices for biological and chemical hazards [9][10]. Future Procurement Plans - The customs authority plans to purchase 30 sets of nuclear radiation detection equipment, including 20 portal vehicle radiation detection devices and 10 portal pedestrian radiation detection devices, scheduled for July 2025 [10][11]. - Additional projects include the procurement of various laboratory instruments and reagents to support daily inspection and quarantine work, ensuring compliance with legal requirements for imported and exported goods [10][11].

Core Viewpoint - The article emphasizes the challenges faced in domestic substitution of scientific instruments in China, including information fragmentation, high verification costs, and risk aversion among decision-makers. It highlights the services provided by the Instrument Information Network to assist users in efficiently and accurately selecting domestic instruments [1][2]. Group 1: Challenges in Domestic Substitution - The lack of reliable data and case studies raises doubts about the performance stability, long-term reliability, precision consistency, and application adaptability of domestic instruments compared to imported ones [3]. - High verification costs deter users from switching to domestic instruments, as the process involves significant investment, reconfiguration of experimental processes, and potential certification risks [3]. - Decision-makers often exhibit a risk-averse mentality, preferring well-known imported brands to avoid accountability in case of issues, which complicates the adoption of new domestic solutions [3]. Group 2: Solutions Offered by Instrument Information Network - The Instrument Information Network has created a comprehensive database of successful domestic instrument substitution cases, technical white papers, performance benchmarks, and user evaluations to provide critical information [4]. - A "Domestic Instrument Selection Database" has been launched, featuring 49,374 domestic scientific instruments across 295 categories, addressing the needs of various laboratory sectors [5]. - The network offers free trial opportunities for specific domestic instruments, facilitating user experience before purchase [7]. Group 3: Events and Community Engagement - The fourth Domestic Good Instruments Trial Offline Matching Conference was successfully held, featuring the release of the "Domestic Good Instruments Manual" and discussions on the development of domestic instruments [8]. - The network has engaged with nearly 100 user units and participated in around 300 vendor interactions, helping users connect with manufacturers for efficient procurement [17]. Group 4: Expert Consultation and Support - A team of experienced consultants provides one-on-one in-depth selection consulting services, tailored to specific application needs, budget constraints, and laboratory environments [10]. - The network acts as a connector, facilitating direct communication with key personnel from leading domestic manufacturers to address resource bottlenecks in major procurement projects [16]. Group 5: User-Centric Approach - The initiative "Domestic Good Instruments" aims to bridge the gap between users and reliable domestic products, enhancing the recognition and acceptance of domestic instruments [11]. - A compilation of 161 selected "Domestic Good Instruments" will be presented to government procurement departments and laboratories to promote independent procurement of domestic scientific instruments [13].

Core Viewpoint - Nanwei Technology is positioned as a leading company in high-performance nano microsphere materials, with significant improvements in performance margins and growth opportunities in the chromatography filler sector due to import substitution and commercialization expansion [2][3][6]. Company Overview - Established in 2007, Nanwei Technology specializes in the R&D, mass production, sales, and application services of high-performance nano microsphere materials for various sectors including biomedicine and diagnostics [2]. - The company faced growth pressures in 2023 due to external macroeconomic changes, but has shown significant performance recovery since Q4 2024, with a quarterly revenue of 233 million yuan, a year-on-year increase of 71.47%, and a net profit of 41 million yuan, up 38.05% [2]. Market Opportunities - The global chromatography media market is projected to grow from 6.9 billion USD in 2023 to 9 billion USD by 2026, with a compound annual growth rate (CAGR) of 9.26%. The Chinese market is expected to grow from 11.2 billion yuan to 20.3 billion yuan in the same period, with a CAGR of 21.92% [3]. - Nanwei Technology is well-positioned to benefit from two major opportunities: import substitution and commercialization expansion. The company has developed a comprehensive range of chromatography fillers and media, making it a key player in the domestic market [3][4]. Import Substitution Opportunity - The chromatography filler and media industry has been historically dominated by foreign companies, with low domestic production rates. The rapid development of the domestic biomedicine industry and geopolitical tensions are driving the need for local alternatives [3]. - Successful project changes by downstream client Heng Rui Pharmaceutical provide a template for future import substitution projects, positioning Nanwei Technology as a leader in this transition [3]. Commercialization Expansion Opportunity - The usage of chromatography fillers and media increases with project phases, from early clinical trials to commercialization. Nanwei Technology has accumulated a growing number of clients and is nurturing numerous mid-to-late clinical projects, which are expected to yield significant returns [4]. Industry Chain Layout - Beyond its core business, Nanwei Technology is expanding its industry chain through a combination of self-built and acquired entities, including subsidiaries focused on chromatography instruments and diagnostic materials [5]. - Key subsidiaries include: - Fuli Instruments, a leader in domestic chromatography instruments, has made strides in gas and liquid chromatography [5]. - NAP Analysis, which focuses on high-quality laboratory chromatography consumables, achieving full domestic production [5]. - Saip Instrument, which develops precision purification equipment for large biomolecules, establishing itself as a leader in the domestic market [5]. Financial Forecast - Revenue projections for Nanwei Technology are 1 billion yuan in 2025, 1.24 billion yuan in 2026, and 1.55 billion yuan in 2027, with corresponding net profits of 141 million yuan, 221 million yuan, and 285 million yuan [6]. - The company is expected to maintain a strong growth trajectory, supported by its leadership in the chromatography filler and media sector and its strategic industry chain expansions [6].

Investment Rating - The investment rating for the company is "Buy" [2]. Core Insights - The company, Nanwei Technology, is a leader in high-performance nano-microsphere materials, with significant improvements in performance margins. The company has faced growth pressures due to external macroeconomic changes since 2023, but has shown notable recovery starting from Q4 2024, with a quarterly revenue of 233 million yuan, a year-on-year increase of 71.47%, and a net profit of 41 million yuan, up 38.05% [4][33]. - The company is positioned to capitalize on two major opportunities in its chromatography filler business: import substitution and commercialization expansion. The global chromatography medium market is projected to grow from 6.9 billion USD in 2023 to 9 billion USD by 2026, with a compound annual growth rate (CAGR) of 9.26%. In China, the market is expected to grow from 11.2 billion yuan in 2023 to 20.3 billion yuan by 2026, with a CAGR of 21.92% [5][18]. - The company is expanding its industrial chain through a dual approach of self-building and acquisitions, enhancing its business extensibility and opening up growth ceilings [7][20]. Summary by Sections Company Overview - Nanwei Technology, established in 2007, specializes in the research, production, and sales of high-performance nano-microsphere materials, serving various sectors including biomedicine, flat panel displays, analytical testing, and in vitro diagnostics. The company aims to become a global leader in microsphere brands [21][23]. Chromatography Filler Business - The chromatography filler and chromatography medium are critical consumables for biopharmaceutical separation and purification. The company has developed a comprehensive range of products, making it a key player in the domestic market. The company is expected to benefit from import substitution and commercialization opportunities, with successful case studies already established [5][18]. Industrial Chain Layout - The company is actively building its industrial chain by acquiring and establishing subsidiaries focused on chromatography instruments, consumables, and purification systems. This strategy is expected to enhance its market position and operational efficiency [7][20]. Financial Forecast and Investment Rating - Revenue projections for the company are 1.001 billion yuan in 2025, 1.244 billion yuan in 2026, and 1.549 billion yuan in 2027, with corresponding net profits of 141 million yuan, 221 million yuan, and 285 million yuan. The company is rated positively due to its leading position in the chromatography filler and medium industry, along with favorable market conditions [8][10].

Investment Rating - The investment rating for the company is "Buy" [2]. Core Insights - The company, Nanwei Technology, is a leader in high-performance nano-microsphere materials, with significant improvements in its performance margins. The company has faced growth pressures due to external macroeconomic changes since 2023, but has shown notable recovery since Q4 2024, achieving a quarterly revenue of 233 million yuan, a year-on-year increase of 71.47%, and a net profit of 41 million yuan, up 38.05% [4][33]. - The company is positioned to capitalize on two major opportunities in its chromatography filler business: import substitution and commercialization expansion. The global chromatography medium market is expected to grow from 6.9 billion USD in 2023 to 9 billion USD by 2026, with a compound annual growth rate (CAGR) of 9.26%. In China, the market is projected to grow from 11.2 billion yuan in 2023 to 20.3 billion yuan by 2026, with a CAGR of 21.92% [5][18]. - The company has established a comprehensive layout in the upstream and downstream of the industry chain, enhancing its growth potential. Through a combination of self-built and acquired subsidiaries, it has expanded into chromatography instruments, consumables, protein purification systems, and in vitro diagnostic consumables [7][20]. Summary by Sections Company Overview - Nanwei Technology, founded in 2007, specializes in the research, production, and sales of high-performance nano-microsphere materials, serving various sectors including biomedicine, flat panel displays, analytical testing, and in vitro diagnostics. The company aims to become a global leader in microsphere technology [4][21]. Chromatography Filler Business - The chromatography filler and chromatography medium are critical consumables for biopharmaceutical separation and purification. The company is well-positioned to benefit from the ongoing import substitution and commercialization expansion in this sector [5][18]. - The company has developed a full range of chromatography fillers and media, making it a key player in the domestic market, which has historically been dominated by foreign brands [5][18]. Financial Projections - Revenue projections for the company from 2025 to 2027 are 1.00 billion yuan, 1.24 billion yuan, and 1.55 billion yuan, respectively. Corresponding net profits are expected to be 141 million yuan, 221 million yuan, and 285 million yuan, with earnings per share (EPS) of 0.35 yuan, 0.55 yuan, and 0.71 yuan [8][10]. Subsidiary Overview - The company has several key subsidiaries, including: 1. Fuli Instruments, a leading domestic chromatography instrument manufacturer [11]. 2. NAP Analysis, focusing on high-quality laboratory chromatography consumables [11]. 3. Saip Instrument, specializing in precision purification equipment for biopharmaceuticals [11][20]. Market Opportunities - The company is expected to benefit from the increasing domestic demand for chromatography fillers and media, driven by the growth of the biopharmaceutical industry and the trend towards import substitution [5][18].